{"id":33742,"date":"2025-10-20T16:17:49","date_gmt":"2025-10-20T10:47:49","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=33742"},"modified":"2025-10-17T16:18:12","modified_gmt":"2025-10-17T10:48:12","slug":"peanut-allergy-treatment-landscape","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/peanut-allergy-treatment-landscape","title":{"rendered":"Peanut Allergy Treatment Space: Expanding Horizons Beyond Traditional Immunotherapy"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a05e953db9a3\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a05e953db9a3\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/peanut-allergy-treatment-landscape\/#PALFORZIA_and_XOLAIR_Established_Peanut_Allergy_Treatments\" >PALFORZIA and XOLAIR: Established Peanut Allergy Treatments<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/peanut-allergy-treatment-landscape\/#Peanut_Allergy_Drugs_Under_Development\" >Peanut Allergy Drugs Under Development<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/peanut-allergy-treatment-landscape\/#Recent_Developments_in_Peanut_Allergy_Treatment_Space\" >Recent Developments in Peanut Allergy Treatment Space<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/peanut-allergy-treatment-landscape\/#What_Lies_Ahead_in_Peanut_Allergy_Treatment\" >What Lies Ahead in Peanut Allergy Treatment?<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Peanut allergy is among the most common and serious types of food allergy, with prevalence increasing over the past few decades, particularly among younger populations. It usually first appears in childhood, with symptoms emerging as early as 4 months of age and most often within the first two years of life. Around <strong>20%<\/strong> of children eventually outgrow their peanut allergy and can tolerate peanuts later without adverse reactions. In the United States, peanut allergy is one of the nine most prevalent food allergies, affecting roughly <strong>1\u20132%<\/strong> of the population.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s 2024 assessment, there were approximately <strong>9.8 million<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/peanut-allergy-epidemiology-forecast-insight\">diagnosed cases of peanut allergy<\/a> across the leading markets. Mild-to-moderate peanut allergy represented the largest burden, impacting nearly <strong>4.9 million<\/strong> individuals in 2024. Trend analyses indicate a steady increase in cases over the study period from 2020 to 2034.<\/p>\n\n\n\n<p>Currently, the primary approach to managing peanut allergy involves strict avoidance of peanuts and the use of an Adrenaline Auto-injector (AAI) to treat allergic reactions when they occur.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-palforzia-and-xolair-established-peanut-allergy-treatments\"><span class=\"ez-toc-section\" id=\"PALFORZIA_and_XOLAIR_Established_Peanut_Allergy_Treatments\"><\/span><strong>PALFORZIA and XOLAIR: Established Peanut Allergy Treatments<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>At present, <strong>Stallergenes Greer\u2019s PALFORZIA<\/strong> and <strong>Roche and Novartis\u2019 XOLAIR<\/strong> remain the only approved therapies offering meaningful treatment options for patients with peanut allergies and their healthcare providers. PALFORZIA became the first <a href=\"https:\/\/www.delveinsight.com\/report-store\/peanut-allergy-market\">FDA-approved drug for peanut allergy<\/a> in children in January 2020, with initial projections estimating sales of <strong>USD 1.28 billion <\/strong>by 2024. However, its market performance fell short of expectations, partly due to challenges from the COVID-19 pandemic and the drug\u2019s complex administration requirements, which necessitated frequent visits to healthcare providers.<\/p>\n\n\n\n<p>On the other hand, XOLAIR is an FDA-approved medication designed to reduce allergic reactions in individuals with one or more food allergies. It is administered as a subcutaneous injection, either by a healthcare professional or by self-injection at home after an initial supervised dose. In February 2024, the FDA expanded XOLAIR\u2019s approval to include the reduction of allergic reactions, including anaphylaxis, from accidental exposure to one or more foods in both adults and children aged 1 year and older with IgE-mediated food allergy.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/peanut-allergy-market\"><img decoding=\"async\" width=\"1024\" height=\"435\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/17161718\/Peanut-Allergy-Market-at-a-Glance-1024x435.webp\" alt=\"Peanut-Allergy-Market-at-a-Glance\" class=\"wp-image-33750\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/17161718\/Peanut-Allergy-Market-at-a-Glance-1024x435.webp 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/17161718\/Peanut-Allergy-Market-at-a-Glance-300x127.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/17161718\/Peanut-Allergy-Market-at-a-Glance-150x64.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/17161718\/Peanut-Allergy-Market-at-a-Glance-768x326.webp 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/17161718\/Peanut-Allergy-Market-at-a-Glance-1536x652.webp 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/17161718\/Peanut-Allergy-Market-at-a-Glance.webp 1920w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p>In March 2025, the FDA approved <strong>OMLYCLO (omalizumab-igec) <\/strong>as the first biosimilar designated interchangeable with XOLAIR for treating IgE-mediated food allergy. Meanwhile, ongoing clinical trials in SLIT, OIT, and EPIT immunotherapies show promising results, with OIT currently standing as the only FDA-approved immunotherapy. Overall, the peanut allergy treatment market is increasingly moving toward immunotherapies and biologics.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-peanut-allergy-drugs-under-development\"><span class=\"ez-toc-section\" id=\"Peanut_Allergy_Drugs_Under_Development\"><\/span><strong>Peanut Allergy Drugs Under Development<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/peanut-allergy-pipeline-insight\">peanut allergy clinical trial landscape<\/a> includes several drugs in the development stage that are expected to be approved in the near future. The emerging landscape holds therapeutic alternatives for treatment, including <strong>Viaskin <\/strong>(DBV Technologies), <strong>PVX108 <\/strong>(Aravax), <strong>Remibrutinib <\/strong>(Novartis), <strong>SLIT tablet <\/strong>(ALK-Abello), and others.&nbsp;<\/p>\n\n\n\n<p><strong>DBV Technologies\u2019 Viaskin Peanut<\/strong> is an epicutaneous immunotherapy (EPIT) that delivers small amounts of peanut protein via a wearable patch to promote desensitization. The therapy has received both <strong>Fast Track and Breakthrough Therapy designations<\/strong> from the US FDA. It is currently being tested in a Phase III clinical trial involving children aged 4\u20137 with peanut allergies. DBV Technologies expects to release top-line results from the <strong>VITESSE trial (NCT05741476)<\/strong> in Q4 2025.<\/p>\n\n\n\n<p><strong>Aravax\u2019s PVX108<\/strong> is an advanced immunotherapy aimed at retraining the immune system. It uses engineered peptides to target T cells and potentially reverse allergic responses selectively. The therapy is currently in a Phase II clinical trial for children and adolescents with peanut allergies.<\/p>\n\n\n\n<p><strong>Novartis\u2019 Remibrutinib<\/strong> is a highly selective, potent, oral covalent Bruton\u2019s Tyrosine Kinase (BTK) inhibitor under development for autoimmune conditions, including chronic spontaneous urticaria, myasthenia gravis, and multiple sclerosis, as well as food allergies and hidradenitis suppurativa. It is presently being evaluated in a Phase II clinical trial for adults with peanut allergies.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/peanut-allergy-market\"><img decoding=\"async\" width=\"1024\" height=\"532\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/17153627\/Emerging-Therapies-for-Peanut-Allergy-1024x532.webp\" alt=\"Emerging-Therapies-for-Peanut-Allergy\" class=\"wp-image-33748\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/17153627\/Emerging-Therapies-for-Peanut-Allergy-1024x532.webp 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/17153627\/Emerging-Therapies-for-Peanut-Allergy-300x156.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/17153627\/Emerging-Therapies-for-Peanut-Allergy-150x78.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/17153627\/Emerging-Therapies-for-Peanut-Allergy-768x399.webp 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/17153627\/Emerging-Therapies-for-Peanut-Allergy-1536x798.webp 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/17153627\/Emerging-Therapies-for-Peanut-Allergy.webp 1920w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p>The anticipated launch of these <a href=\"https:\/\/www.delveinsight.com\/report-store\/peanut-allergy-pipeline-insight\">emerging peanut allergy therapies<\/a> are poised to transform the treatment market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the peanut allergy treatment market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-recent-developments-in-peanut-allergy-treatment-space\"><span class=\"ez-toc-section\" id=\"Recent_Developments_in_Peanut_Allergy_Treatment_Space\"><\/span><strong>Recent Developments in Peanut Allergy Treatment Space<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<ul class=\"wp-block-list\">\n<li>In <strong>March 2025, DBV Technologies<\/strong> reached an understanding with the US FDA based on written replies to its Type D IND meeting request. The FDA concurred with DBV\u2019s proposal that safety exposure data from the VITESSE Phase III study of the Viaskin Peanut Patch in children aged 4\u20137 years would be sufficient to support BLA filing for this age group, thereby accelerating the anticipated timeline for BLA submission to the first half of 2026.<\/li>\n\n\n\n<li>In <strong>March 2025,<\/strong> the US FDA approved OMLYCLO (omalizumab-igec) as the first interchangeable biosimilar for reference XOLAIR and the first respiratory biosimilar for the treatment of moderate-to-severe persistent asthma, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), IgE-mediated food allergy, and Chronic Spontaneous Urticaria (CSU).<\/li>\n\n\n\n<li>In <strong>March 2025, DBV Technologies<\/strong> announced a financing of up to USD 306.9 million (EUR 284.5 million), comprising gross proceeds of USD 125.5 million (EUR 116.3 million) to be received upon closing and up to an additional USD 181.4 million (EUR 168.2 million) in gross proceeds contingent upon the full exercise of warrants, subject to the satisfaction of specified conditions.\u00a0<\/li>\n\n\n\n<li>In <strong>February 2025, Stallergenes Greer<\/strong> launched PALFORZIA in the US to treat toddler patients, ages 1\u20133 years, with a confirmed diagnosis of peanut allergy. The FDA approved the expanded indication for toddler patients (ages 1\u20133 years) in July 2024 based on the data from the Phase III POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization) study that was published in the New England Journal of Medicine Evidence in 2023.<\/li>\n\n\n\n<li>In <strong>January 2025, <\/strong>the European Commission approved the extension of the indication of PALFORZIA for the treatment of toddlers (ages 1\u20133) with a confirmed diagnosis of peanut allergy. The marketing authorization covered all 27 European member states and the three European Economic Area states (Iceland, Liechtenstein, and Norway).<\/li>\n<\/ul>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-lies-ahead-in-peanut-allergy-treatment\"><span class=\"ez-toc-section\" id=\"What_Lies_Ahead_in_Peanut_Allergy_Treatment\"><\/span><strong>What Lies Ahead in Peanut Allergy Treatment?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The landscape of peanut allergy treatment is rapidly evolving, moving beyond traditional avoidance strategies and emergency interventions. The total <a href=\"https:\/\/www.delveinsight.com\/report-store\/peanut-allergy-market\">peanut allergy market size<\/a> in the 7MM was estimated to be nearly <strong>USD 400 million<\/strong> in 2024, and it is expected to grow positively at a <strong>CAGR of 16%<\/strong> by 2034. This change is primarily attributed to the adoption of recently approved therapies, the emergence of new treatments, an increase in diagnoses, and rising costs.<\/p>\n\n\n\n<p>One of the most promising approaches on the horizon is oral and epicutaneous immunotherapy, which aims to desensitize patients by gradually introducing controlled amounts of peanut protein. Epicutaneous immunotherapy, delivered via a wearable patch, offers a less invasive alternative to oral routes, potentially reducing the risk of severe allergic reactions while still building tolerance. Clinical trials are showing encouraging results, particularly in younger children, where early intervention could reshape immune responses and improve quality of life.<\/p>\n\n\n\n<p>Looking forward, research is also exploring biologic therapies, such as <a href=\"https:\/\/www.delveinsight.com\/report-store\/monoclonal-antibodies-competitive-landscape\">monoclonal antibodies<\/a>, that target the underlying immune mechanisms driving allergic reactions. These therapies could complement or even replace existing desensitization methods, offering personalized treatment options based on an individual\u2019s risk profile and immune response.&nbsp;<\/p>\n\n\n\n<p>Additionally, combination strategies, pairing biologics with immunotherapy, are under investigation, aiming to enhance safety and efficacy while shortening treatment duration. As our understanding of peanut allergy deepens, the future may hold not only better symptom management but also the possibility of long-term tolerance, transforming the outlook for millions of individuals affected by this condition.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/peanut-allergy-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/17153517\/Peanut-Allergy-Market-Outlook-1024x194.webp\" alt=\"Peanut Allergy Market Outlook\" class=\"wp-image-33746\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/17153517\/Peanut-Allergy-Market-Outlook-1024x194.webp 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/17153517\/Peanut-Allergy-Market-Outlook-300x57.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/17153517\/Peanut-Allergy-Market-Outlook-150x28.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/17153517\/Peanut-Allergy-Market-Outlook-768x145.webp 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/17153517\/Peanut-Allergy-Market-Outlook-1536x291.webp 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/17153517\/Peanut-Allergy-Market-Outlook.webp 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Peanut allergy is among the most common and serious types of food allergy, with prevalence increasing over the past few decades, particularly among younger populations. It usually first appears in childhood, with symptoms emerging as early as 4 months of age and most often within the first two years of life. Around 20% of children [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":33744,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[6428,2193,17793,17794,18002,21844],"industry":[17225],"therapeutic_areas":[17227],"class_list":["post-33742","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-palforzia","tag-peanut-allergy","tag-peanut-allergy-market","tag-peanut-allergy-pipeline","tag-peanut-allergy-treatment","tag-xolair","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Peanut Allergy Treatment Heats Up with New MoAs<\/title>\n<meta name=\"description\" content=\"The landscape of peanut allergy treatment is rapidly evolving, moving beyond traditional avoidance strategies and emergency interventions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/peanut-allergy-treatment-landscape\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Peanut Allergy Treatment Heats Up with New MoAs\" \/>\n<meta property=\"og:description\" content=\"The landscape of peanut allergy treatment is rapidly evolving, moving beyond traditional avoidance strategies and emergency interventions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/peanut-allergy-treatment-landscape\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-20T10:47:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/17153408\/peanut-allergy-treatment-landscape.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Peanut Allergy Treatment Heats Up with New MoAs","description":"The landscape of peanut allergy treatment is rapidly evolving, moving beyond traditional avoidance strategies and emergency interventions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/peanut-allergy-treatment-landscape","og_locale":"en_US","og_type":"article","og_title":"Peanut Allergy Treatment Heats Up with New MoAs","og_description":"The landscape of peanut allergy treatment is rapidly evolving, moving beyond traditional avoidance strategies and emergency interventions.","og_url":"https:\/\/www.delveinsight.com\/blog\/peanut-allergy-treatment-landscape","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-10-20T10:47:49+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/17153408\/peanut-allergy-treatment-landscape.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/peanut-allergy-treatment-landscape","url":"https:\/\/www.delveinsight.com\/blog\/peanut-allergy-treatment-landscape","name":"Peanut Allergy Treatment Heats Up with New MoAs","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/peanut-allergy-treatment-landscape#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/peanut-allergy-treatment-landscape#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/17153408\/peanut-allergy-treatment-landscape.webp","datePublished":"2025-10-20T10:47:49+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"The landscape of peanut allergy treatment is rapidly evolving, moving beyond traditional avoidance strategies and emergency interventions.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/peanut-allergy-treatment-landscape"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/peanut-allergy-treatment-landscape#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/17153408\/peanut-allergy-treatment-landscape.webp","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/17153408\/peanut-allergy-treatment-landscape.webp","width":466,"height":284,"caption":"peanut-allergy-treatment-landscape"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/17153408\/peanut-allergy-treatment-landscape-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Palforzia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">peanut allergy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Peanut Allergy Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Peanut Allergy Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Peanut Allergy Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Xolair<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Palforzia<\/span>","<span class=\"advgb-post-tax-term\">peanut allergy<\/span>","<span class=\"advgb-post-tax-term\">Peanut Allergy Market<\/span>","<span class=\"advgb-post-tax-term\">Peanut Allergy Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Peanut Allergy Treatment<\/span>","<span class=\"advgb-post-tax-term\">Xolair<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 months ago","modified":"Updated 7 months ago"},"absolute_dates":{"created":"Posted on Oct 20, 2025","modified":"Updated on Oct 17, 2025"},"absolute_dates_time":{"created":"Posted on Oct 20, 2025 4:17 pm","modified":"Updated on Oct 17, 2025 4:18 pm"},"featured_img_caption":"peanut-allergy-treatment-landscape","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33742","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=33742"}],"version-history":[{"count":3,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33742\/revisions"}],"predecessor-version":[{"id":33751,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33742\/revisions\/33751"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/33744"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=33742"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=33742"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=33742"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=33742"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=33742"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}